Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
PJT Partners enters its October 27 earnings with a fresh downgrade on the tape and a share price that has shed nearly a quarter of its value in thirty days, a stark reversal for a stock that spent much of the summer near record highs.
The most consequential development this week came from Keefe, Bruyette & Woods. Alex Bond cut his rating to Market Perform from Outperform on October 7, slashing his target from $195 to $159. That move is striking precisely because Bond raised the same target twice in the prior three months, taking it from $175 to $185 in July and then to $195 after the last earnings print. Goldman Sachs also trimmed its target last week, taking it from $203 to $182 while keeping a Buy rating. The direction of travel is clear: the Street still broadly likes the model but is pulling in its horns on valuation after the stock's run earlier this year. The consensus mean price target is $168, implying modest upside from the current close of $139.65, though the gap has narrowed considerably since the summer. BMO Capital, which raised its Outperform target to $194 in August, now stands as the outlier bull on the register.
The borrow market tells a notably relaxed story given the price action. Availability has expanded sharply, rising 34% over the past week to 672%, meaning more than six times as many shares sit available to borrow as are currently shorted. That is among the loosest conditions of the past year, far removed from the 52-week tightest reading of 192%. Cost to borrow has drifted lower too, now running at 0.39%, down roughly 12% over the past month. Short interest at 7.7% of free float is meaningful but has been quietly falling, down 3.3% on the week and roughly flat over the past month. The ORTEX short score has eased from 53.3 at its recent peak on September 24 to 50.5 today, sitting right at the neutral midpoint. None of this suggests a short-driven selloff. The bears have not materially added conviction even as the stock dropped.
The valuation picture helps explain why analysts are recalibrating. The price-to-earnings multiple has compressed to 16.4x, down 4.5 turns over the past thirty days, while price-to-book has shed 1.3 points to 4.7x over the same period. That re-rating reflects the scale of the drawdown rather than an earnings revision. Factor scores present a mixed picture. The dividend score ranks in the 92nd percentile, the company's capital return record remains strong. EPS surprise history is solid at the 70th percentile, and 90-day earnings momentum scores 74. What weighs against the setup is weaker 30-day earnings momentum at 47, a below-average forward EPS growth score of 35, and a short score rank of just 21, consistent with the short base that does exist being moderately elevated relative to peers. Options positioning is unremarkable: the put/call ratio is 0.73, essentially in line with its 20-day average of 0.71, with a z-score of just 0.32. No unusual hedging demand is visible ahead of earnings.
The insider register skews negative in recent months, though not dramatically so. Directors sold a combined net of approximately $2.1 million worth of stock in open-market transactions over the past 90 days, with three separate director sales in late August at prices ranging from $167 to $175. None of those trades were flagged as made under a 10b5-1 plan, which makes them discretionary rather than scheduled. No buying has appeared. On the institutional side, BlackRock added 382,000 shares as recently as September 30, and Wasatch Advisors built a position of nearly 1.5 million shares as of June. Those are stabilising forces, though BlackRock's passive 13G filing shows a slight reduction from 15.2% to 14.2% of class since last disclosed. There are no 13D activists on the register.
Wikipedia attention for PJT spiked to a z-score of 2.7 against its own 90-day history as of late September, the highest retail attention reading the alt data layer tracks for this stock. That spike coincides with the sharp price move lower, attention driven by a selloff rather than a positive catalyst. With Q3 results due October 27, the question ahead of the print is whether the deal flow and fundraising environment that management pointed to positively last quarter has held up, or whether the KBW downgrade reflects a more cautious read on what those numbers will show.
See the live data behind this article on ORTEX.
Open PJT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
